These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34497515)

  • 1. mTOR-Inhibition and COVID-19 in Kidney Transplant Recipients: Focus on Pulmonary Fibrosis.
    Granata S; Carratù P; Stallone G; Zaza G
    Front Pharmacol; 2021; 12():710543. PubMed ID: 34497515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR Inhibitor Use Is Associated With a Favorable Outcome of COVID-19 in Patients of Kidney Transplant: Results of a Retrospective Study.
    Pinchera B; Spirito L; Buonomo AR; Foggia M; Carrano R; Salemi F; Schettino E; Papa F; La Rocca R; Crocetto F; Napolitano L; Villari R; Gentile I
    Front Med (Lausanne); 2022; 9():852973. PubMed ID: 35801204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of disease severity and outcome of hospitalized renal transplant recipients with COVID-19 infection: a systematic review of a globally representative sample.
    Hasan I; Rashid T; Suliman S; Amer H; Chirila RM; Mai ML; Jarmi T; Khouzam S; Franco PM; Heilig CW; Wadei HM
    Rom J Intern Med; 2021 Mar; 59(1):10-42. PubMed ID: 33155999
    [No Abstract]   [Full Text] [Related]  

  • 4. Covid-19 in liver transplant recipients: the French SOT COVID registry.
    Dumortier J; Duvoux C; Roux O; Altieri M; Barraud H; Besch C; Caillard S; Coilly A; Conti F; Dharancy S; Durand F; Francoz C; Garaix F; Houssel-Debry P; Kounis I; Lassailly G; Laverdure N; Leroy V; Mallet M; Mazzola A; Meunier L; Radenne S; Richardet JP; Vanlemmens C; Hazzan M; Saliba F; ;
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101639. PubMed ID: 33636654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
    Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants.
    Caillard S; Anglicheau D; Matignon M; Durrbach A; Greze C; Frimat L; Thaunat O; Legris T; Moal V; Westeel PF; Kamar N; Gatault P; Snanoudj R; Sicard A; Bertrand D; Colosio C; Couzi L; Chemouny JM; Masset C; Blancho G; Bamoulid J; Duveau A; Bouvier N; Chavarot N; Grimbert P; Moulin B; Le Meur Y; Hazzan M;
    Kidney Int; 2020 Dec; 98(6):1549-1558. PubMed ID: 32853631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation].
    Caletti C; Granata S; Tomei P; Lupo A; Zaza G
    G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.
    Elens L; Langman LJ; Hesselink DA; Bergan S; Moes DJAR; Molinaro M; Venkataramanan R; Lemaitre F
    Ther Drug Monit; 2020 Jun; 42(3):360-368. PubMed ID: 32304488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Guidance on the special care of liver or kidney transplant recipients diagnosed with COVID-19].
    Remport Á; Gerlei Z; Cseprekál O; Wagner L; Földes K; Marton A; Patonai A; Török S; Haboub-Sandil A; Varga M; Doros A; Smudla A; Fazakas J; Kóbori L
    Orv Hetil; 2020 Aug; 161(32):1310-1321. PubMed ID: 32750019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up and Management of Kidney Transplant Recipients During the COVID-19 Lockdown: The Experience of an Italian Transplant Center, Including Two Cases of COVID-19 Pneumonia.
    Binda B; Picchi G; Carucci AC; Sinatti G; Di Norcia M; Grimaldi A; Lancione L; Natili A; Chiappori D; Montali F; Lupi D; Martinez V; Panarese A; D'anselmi F; Pisani F
    Transplant Proc; 2020 Nov; 52(9):2614-2619. PubMed ID: 32709413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR-inhibitors and post-transplant diabetes mellitus: a link still debated in kidney transplantation.
    Granata S; Mercuri S; Troise D; Gesualdo L; Stallone G; Zaza G
    Front Med (Lausanne); 2023; 10():1168967. PubMed ID: 37250653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus in a Renal Transplant Recipient Infected With COVID-19: A Blessing in Disguise?
    Talwar D; Kumar S; Acharya S; Hulkoti V; Annadatha A
    Cureus; 2021 Aug; 13(8):e17102. PubMed ID: 34527488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
    Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
    Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
    [No Abstract]   [Full Text] [Related]  

  • 15. [Severe acute respiratory syndrome coronavirus 2 infection in renal transplant recipients: A case report].
    Li QY; Cheng Q; Zhao ZL; Dai NN; Zeng L; Zhu L; Guo W; Li C; Wang JH; Li S; Ge QG; Shen N
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 52(4):780-784. PubMed ID: 32773818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
    Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
    J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients.
    Colmenero J; Rodríguez-Perálvarez M; Salcedo M; Arias-Milla A; Muñoz-Serrano A; Graus J; Nuño J; Gastaca M; Bustamante-Schneider J; Cachero A; Lladó L; Caballero A; Fernández-Yunquera A; Loinaz C; Fernández I; Fondevila C; Navasa M; Iñarrairaegui M; Castells L; Pascual S; Ramírez P; Vinaixa C; González-Dieguez ML; González-Grande R; Hierro L; Nogueras F; Otero A; Álamo JM; Blanco-Fernández G; Fábrega E; García-Pajares F; Montero JL; Tomé S; De la Rosa G; Pons JA
    J Hepatol; 2021 Jan; 74(1):148-155. PubMed ID: 32750442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM; Kushwaha SS
    Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review.
    Paoletti E; Citterio F; Corsini A; Potena L; Rigotti P; Sandrini S; Bussalino E; Stallone G;
    J Nephrol; 2020 Feb; 33(1):69-82. PubMed ID: 31028549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of mTOR inhibitors on the development of malignancy.
    Geissler EK
    Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.